Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $7.67 and traded as low as $5.72. Sage Therapeutics shares last traded at $5.85, with a volume of 722,997 shares.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on SAGE. Raymond James reiterated a "market perform" rating on shares of Sage Therapeutics in a research report on Thursday, October 10th. Royal Bank of Canada raised shares of Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 price objective on the stock in a research note on Thursday, November 21st. Piper Sandler decreased their target price on shares of Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, January 2nd. Bank of America dropped their price target on shares of Sage Therapeutics from $11.00 to $6.00 and set an "underperform" rating on the stock in a research report on Wednesday, October 9th. Finally, Robert W. Baird cut their price objective on shares of Sage Therapeutics from $13.00 to $9.00 and set a "neutral" rating for the company in a report on Wednesday, October 9th. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $10.53.
Read Our Latest Analysis on Sage Therapeutics
Sage Therapeutics Trading Down 5.1 %
The company has a fifty day simple moving average of $5.58 and a 200-day simple moving average of $7.66. The company has a market capitalization of $339.51 million, a PE ratio of -0.99 and a beta of 0.91.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts' consensus estimates of ($1.52) by ($0.01). The business had revenue of $11.87 million for the quarter, compared to analysts' expectations of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The business's revenue for the quarter was up 337.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.81) earnings per share. On average, equities analysts predict that Sage Therapeutics, Inc. will post -6.53 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of SAGE. Quest Partners LLC lifted its position in shares of Sage Therapeutics by 14.5% during the second quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company's stock worth $128,000 after purchasing an additional 1,486 shares in the last quarter. AdvisorShares Investments LLC increased its stake in Sage Therapeutics by 13.6% during the 2nd quarter. AdvisorShares Investments LLC now owns 16,030 shares of the biopharmaceutical company's stock worth $177,000 after buying an additional 1,918 shares during the period. Headlands Technologies LLC lifted its holdings in Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company's stock worth $43,000 after buying an additional 2,782 shares in the last quarter. Geode Capital Management LLC boosted its position in Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock valued at $8,975,000 after buying an additional 3,757 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Sage Therapeutics by 66.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company's stock worth $85,000 after acquiring an additional 4,672 shares in the last quarter. 99.22% of the stock is currently owned by hedge funds and other institutional investors.
About Sage Therapeutics
(
Get Free Report)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Recommended Stories
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
